e-learning
resources
Barcelona 2010
Tuesday, 21.09.2010
Treatment of lung cancer
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Selective adjuvant chemotherapy according to in-vitro chemoresistance test: Long term follow up of patients with resectable non-small cell lung cancer (NSCLC) stage IIIA
V. Kolek, M. Hajduch, I. Grygarkova, J. Klein (Olomouc, Czech Republic)
Source:
Annual Congress 2010 - Treatment of lung cancer
Session:
Treatment of lung cancer
Session type:
Thematic Poster Session
Number:
5049
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
V. Kolek, M. Hajduch, I. Grygarkova, J. Klein (Olomouc, Czech Republic). Selective adjuvant chemotherapy according to in-vitro chemoresistance test: Long term follow up of patients with resectable non-small cell lung cancer (NSCLC) stage IIIA. Eur Respir J 2010; 36: Suppl. 54, 5049
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
Related content which might interest you:
Combination of neoadjuvant and adjuvant chemotherapy in marginally resectable IIIA nonsmall cell lung cancer (NSCLC): long-term follow up
Source: Eur Respir J 2006; 28: Suppl. 50, 772s
Year: 2006
Role of chemotherapy in stage III non-small cell lung cancer (NSCLC): adjuvant or induction?
Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer
Year: 2006
Treatment of unresectable locoregional (stage III) non-small cell lung cancer
Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment
Year: 2005
Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy?
Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies
Year: 2007
Neo-adjuvant chemotherapy: level of evidence in early stage and in marginally resectable disease
Source: Annual Congress 2005 - Multidisciplinary treatment of non-metastatic non-small cell lung cancer: contemporary concepts
Year: 2005
Treatment of potentially resectable locoregional (stage III) non-small cell lung cancer
Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment
Year: 2005
Treatment tolerance and survival in elderly patients with stage IV non-small cell lung cancer (NSCLC)
Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology
Year: 2019
Adjuvant chemotherapy in stage IB nonsmall cell lung cancer
Source: Breathe 2009; 5: 361
Year: 2009
Surgical multimodality treatment for stage III non-small cell lung cancer (NSCLC)
Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer
Year: 2006
First- and second-line therapy for advanced nonsmall cell lung cancer
Source: Eur Respir J 2009; 33: 915-930
Year: 2009
Radiotherapy for stage III non-small cell lung cancer (NSCLC)
Source: European Multidisciplinary Conference in Thoracic Oncology 2009
Year: 2009
Response to chemotherapy as a predictor of survival in advanced non-small cell lung cancer (NSCLC)
Source: International Congress 2015 – Diagnosis and therapy of lung cancer
Year: 2015
Hyper-progressive disease in patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo)
Source: International Congress 2018 – Lung cancer: modern therapies and beyond
Year: 2018
Lung function evaluation in gemcitabine and concurrent radiotherapy treatment in nonsmall cell lung cancer (NSCLC)
Source: Eur Respir J 2001; 18: Suppl. 33, 376s
Year: 2001
Impact of neoadjuvant therapy on tumor resectability and survival of patients with locally advanced non-small cell lung cancer
Source: Annual Congress 2011 - General thoracic surgery II
Year: 2011
Stage IIIA-N2 non-small cell lung cancer (NSCLC): comparison of prognostic factors in 257 patients treated with surgery (S) versus induction chemotherapy plus surgery (IC+S)
Source: Eur Respir J 2002; 20: Suppl. 38, 597s
Year: 2002
Use of adjuvants to chemotherapy in stage IV nonsmall cell lung carcinoma (NSCLC)
Source: Eur Respir J 2003; 22: Suppl. 45, 64s
Year: 2003
The 7-year results of the surgical treatment of non-small cell lung cancer (NSCLC) patients and the influence of neoadjuvant treatment
Source: Annual Congress 2007 - Therapy of thoracic malignancies
Year: 2007
24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC)
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept